Navigation Links
Watson Reaches Settlement with Mallinckrodt Over Exalgo(R)
Date:1/26/2012

istorical facts are forward-looking statements that reflect Watson's current perspective of existing information as of the date of this release. It is important to note that Watson's goals and expectations are not predictions of actual performance. Actual results may differ materially from Watson's current expectations depending upon a number of factors, risks and uncertainties affecting Watson's business. These factors include, among others, the impact of competitive products and pricing; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson and its third party manufacturers' facilities, products and/or businesses; changes in the laws and regulations, including Medicare and Medicaid, affecting among other things, pricing and reimbursement of pharmaceutical products; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's quarterly report on form 10-Q for the quarter ended September 30, 2011 and Watson's annual report on Form 10-K for the year ended December 31, 2010. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements.

Exalgo® is a registered trademark of Mallinckrodt LLC. CONTACTS:Investors: 

Patty Eisenhaur  

(862) 261-8141 

  Media: 

Charlie Mayr 

(862) 261-8030(Logo: http://photos.prnewswire.com/prnh/20100121/LA41294LOGO )


'/>"/>
SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Watson Launches Generic Biaxin(R) XL
2. Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
3. Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia
4. Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder
5. Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
6. Watson and Barr Settle Lawsuit Over Oxytrol(R)
7. Watson to Host Conference Call and Webcast to Discuss Fourth Quarter 2009 Earnings and 2010 Outlook
8. Watson Completes Acquisition of Eden Biodesign
9. Watson to Present at Credit Suisse Healthcare Conference
10. Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy
11. Watson Files FDA Application for Generic Rozerem(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 21, 2014  Heated dialogue in recent months about ... cancer treatments to Gilead,s new hepatitis C drug Harvoni® ... world questioning what it means to put a price ... And while drug pricing is one of the ... both a general business and ethical standpoint – it ...
(Date:11/21/2014)... N.J. , Nov. 21, 2014  PTC Therapeutics, Inc. ... the 2014 Legend of Technology Award for Vision, Innovation, and ... Ph.D., Chief Executive Officer. This award recognizes an individual who ... New Jersey for several decades. ... Technology Award," stated Stuart Peltz , Ph.D., CEO of ...
(Date:11/21/2014)... , Nov. 21, 2014 ... European Medicines Agency (EMA) has granted Orphan ... lead product candidate, for the treatment of ... rare, severely disabling genetic disease characterized by ... (flare-ups) and new abnormal bone formation. This ...
Breaking Medicine Technology:"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 2"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 3"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 4"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 5PTC Therapeutics Announces CEO, Dr. Stuart Peltz Recipient of The New Jersey Technology Council's 2014 Legend of Technology Award 2PTC Therapeutics Announces CEO, Dr. Stuart Peltz Recipient of The New Jersey Technology Council's 2014 Legend of Technology Award 3Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 2Clementia Pharmaceuticals Receives EMA Orphan Medicinal Product Designation for Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva 3
... Reportlinker.com announces that a new ... its catalogue: Women,s ... to 2016 - High Unmet Need ... Drugs in the Menopause and Osteoporosis ...
... ST. LOUIS, Oct. 6, 2011 Express Scripts, Inc. ... guidance with respect to anticipated future financial results.  This ... and expectations, and, as stated in the Company,s various ... those originally projected or suggested in such guidance for ...
Cached Medicine Technology:Women's Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets 2Women's Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets 3Women's Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets 4Women's Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets 5Women's Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets 6Women's Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets 7Women's Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets 8Women's Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets 9Women's Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets 10Women's Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets 11Women's Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets 12Women's Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets 13Express Scripts Announces Revised 2011 Financial Guidance 2Express Scripts Announces Revised 2011 Financial Guidance 3Express Scripts Announces Revised 2011 Financial Guidance 4Express Scripts Announces Revised 2011 Financial Guidance 5Express Scripts Announces Revised 2011 Financial Guidance 6Express Scripts Announces Revised 2011 Financial Guidance 7Express Scripts Announces Revised 2011 Financial Guidance 8Express Scripts Announces Revised 2011 Financial Guidance 9Express Scripts Announces Revised 2011 Financial Guidance 10
(Date:11/21/2014)... News) -- The cost of diabetes care in the ... climbing to more than $322 billion annually, a new ... seen with prediabetes care, which have risen 74 percent, ... researchers added. In 2012, excess medical costs and ... for every American. That total includes $244 billion in ...
(Date:11/21/2014)... (PRWEB) November 21, 2014 Center for ... workshops titled “Massachusetts Insurance Funding for Autism Workshops” to ... navigate their way through the insurance coverage process. ... Massachusetts law and the most effective ways to access ... Dec. 4 from 6-8:00 p.m. at 331 Montvale Ave., ...
(Date:11/21/2014)... Recently, VogueQueen has released ... dress promotion for the coming holiday season. People who ... when checking out. , The beach wedding dresses from ... like the designs for the premium quality fabrics and ... be good for the environment, they would bring more ...
(Date:11/21/2014)... 21, 2014 For many busy people, having ... visits and months of recovery from dental surgery that have ... at the cost of their youthful appearance. , But the ... Institute in Oxnard and Woodland Hills, Calif., can provide someone ... even in instances where the patient’s bone has deteriorated. , ...
(Date:11/21/2014)... TopConsumerReviews.com recently awarded their highest ... in the relief of depression symptoms. ... sadness and depression each year and are unable ... prescription drugs can produce worse side effects than ... and require regular follow-up visits with a doctor. ...
Breaking Medicine News(10 mins):Health News:Cost of Diabetes Care Keeps Climbing, Report Shows 2Health News:Center for Autism and Related Disorders to Host Massachusetts Autism Insurance Workshops for Parents 2Health News:Beach Wedding Dresses on Sale for the Coming Holiday Season at VogueQueen.com 2Health News:Anacapa Dental Art Institute Prosthodontists Develop New Technique to Offer Younger Appearance in Just One Visit 2Health News:Anacapa Dental Art Institute Prosthodontists Develop New Technique to Offer Younger Appearance in Just One Visit 3Health News:Anacapa Dental Art Institute Prosthodontists Develop New Technique to Offer Younger Appearance in Just One Visit 4Health News:Anacapa Dental Art Institute Prosthodontists Develop New Technique to Offer Younger Appearance in Just One Visit 5Health News:Depression Relief Product Receives Top 5-Star Rating from TopConsumerReviews.com 2
... Dental disease could be developing earlier than thought. Reports ... people has showed that periodontal disease, characterized by bacteria ... teeth is associated with an early onset, contrary to ... 30s., ,Inflammation in the mouth caused by such ...
... drug resistance across the world., ,According to a ... Lancet, worldwide resistance to drugs used to treat ... ,Adamantanes have been used to treat influenza A ... studies have identified a low incidence of resistance to ...
... that arise from the teeth, called dentigerous cysts, may be ... certain infections in the head and neck area., ,Dentigerous ... facial swelling and delayed tooth eruption. However, head and neck ... as recurrent head and neck infections or as a deep ...
... Reliance Infocomm, one of India's leading telecom companies, said ... Apollo Hospitals to provide telemedicine services in over 100 ... will leverage Reliance Infocomm's nationwide chain of 240 WebWorld ... services. , ,Reliance WebWorld will offer access to ...
... over the past fifty years, new nutrition-related problems ... and is occurring on a continuum. While problems ... to exist, increasingly problems of diet/chronic diseases are ... demographic shift has resulted in increased life expectancy ...
... Researchers from the Technion-Israel Institute of Technology Sleep Laboratory ... deficit hyperactivity disorder (ADHD) may need more sleep than ... their problem., ,ADHD is considered an issue of ... and over stimulated. Yet, the use of stimulant medications ...
Cached Medicine News:Health News:Dental Cysts Can Cause Infections In Head And Neck 2Health News:Children With ADHD May Just Be Sleepy 2
The Freedom Clear® LS Long Seal is a 100% latex-free, self-adhering, one piece catheter with an ultra-thin sheath for everyday wear. Its long seal provides added security....
The UltraFlex® all silicone self-adhering male external catheter is 100% latex-free and eliminates the risk of latex-related skin irritations. This breathable catheter promotes healthy skin and i...
Used as a percutaneous entry needle to introduce wire guides. The coaxial design reduces potential A.V. malformations. Supplied sterile in peel-open packages. Intended for one-time use....
... Used for stone manipulation ... tract. Enhanced wire strength permits ... ureter more readily than standard ... facilitates easy, ergonomic one-handed operation. ...
Medicine Products: